CN115708533A - Functional tea for preventing and improving cardiovascular and cerebrovascular diseases and preparation method thereof - Google Patents
Functional tea for preventing and improving cardiovascular and cerebrovascular diseases and preparation method thereof Download PDFInfo
- Publication number
- CN115708533A CN115708533A CN202211280653.0A CN202211280653A CN115708533A CN 115708533 A CN115708533 A CN 115708533A CN 202211280653 A CN202211280653 A CN 202211280653A CN 115708533 A CN115708533 A CN 115708533A
- Authority
- CN
- China
- Prior art keywords
- parts
- raw materials
- tea
- preventing
- cerebrovascular diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000020542 functional tea Nutrition 0.000 title claims abstract description 48
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 22
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 22
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 240000000249 Morus alba Species 0.000 claims abstract description 14
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 14
- 230000001954 sterilising effect Effects 0.000 claims abstract description 14
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 12
- 235000008584 Hovenia dulcis Nutrition 0.000 claims abstract description 11
- 244000010000 Hovenia dulcis Species 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 11
- 241000233779 Cyclocarya paliurus Species 0.000 claims abstract description 10
- 238000009835 boiling Methods 0.000 claims abstract description 10
- 235000018597 common camellia Nutrition 0.000 claims abstract description 10
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 9
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 9
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 9
- 229940087559 grape seed Drugs 0.000 claims abstract description 8
- 238000001816 cooling Methods 0.000 claims abstract description 7
- 238000005303 weighing Methods 0.000 claims abstract description 6
- 241001122767 Theaceae Species 0.000 claims abstract description 4
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 2
- 230000035622 drinking Effects 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 241000209507 Camellia Species 0.000 claims 1
- 240000001548 Camellia japonica Species 0.000 abstract description 9
- 230000002503 metabolic effect Effects 0.000 abstract description 4
- 235000013361 beverage Nutrition 0.000 abstract description 2
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 210000003813 thumb Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 30
- 244000269722 Thea sinensis Species 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 235000013616 tea Nutrition 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 230000001603 reducing effect Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 12
- 229920006008 lipopolysaccharide Polymers 0.000 description 12
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 11
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 11
- 241000229143 Hippophae Species 0.000 description 11
- 239000006286 aqueous extract Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- 229930003935 flavonoid Natural products 0.000 description 10
- 235000017173 flavonoids Nutrition 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 240000006365 Vitis vinifera Species 0.000 description 9
- 235000014787 Vitis vinifera Nutrition 0.000 description 9
- 210000001715 carotid artery Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 150000002215 flavonoids Chemical class 0.000 description 9
- 235000009754 Vitis X bourquina Nutrition 0.000 description 8
- 235000012333 Vitis X labruscana Nutrition 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 244000235603 Acacia catechu Species 0.000 description 4
- 235000006020 Acacia catechu Nutrition 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000001560 acacia catechu Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000004900 autophagic degradation Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 235000018927 edible plant Nutrition 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 238000010298 pulverizing process Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004781 brain capillary Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- -1 flavonoid compound Chemical class 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 3
- 235000005875 quercetin Nutrition 0.000 description 3
- 229960001285 quercetin Drugs 0.000 description 3
- 235000021283 resveratrol Nutrition 0.000 description 3
- 229940016667 resveratrol Drugs 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000003861 Ribosomal protein S6 Human genes 0.000 description 2
- 108090000221 Ribosomal protein S6 Proteins 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 201000007930 alcohol dependence Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001237431 Anomala Species 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 241000233778 Cyclocarya Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 101001052506 Homo sapiens Microtubule-associated proteins 1A/1B light chain 3A Proteins 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 102100024178 Microtubule-associated proteins 1A/1B light chain 3A Human genes 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 102000000344 Sirtuin 1 Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000003840 blood vessel health Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 235000020934 caloric restriction Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 230000004149 ethanol metabolism Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- SQOJOAFXDQDRGF-WJHVHIKBSA-N ginkgolide B Natural products O=C1[C@@H](C)[C@@]2(O)[C@@H]([C@H](O)[C@]34[C@@H]5OC(=O)[C@]23O[C@H]2OC(=O)[C@H](O)[C@@]42[C@H](C(C)(C)C)C5)O1 SQOJOAFXDQDRGF-WJHVHIKBSA-N 0.000 description 1
- SQOJOAFXDQDRGF-MMQTXUMRSA-N ginkgolide-b Chemical compound O[C@H]([C@]12[C@H](C(C)(C)C)C[C@H]3OC4=O)C(=O)O[C@H]2O[C@]24[C@@]13[C@@H](O)[C@@H]1OC(=O)[C@@H](C)[C@]21O SQOJOAFXDQDRGF-MMQTXUMRSA-N 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 108091008147 housekeeping proteins Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000030097 organ senescence Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000005962 plant activator Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 208000004124 rheumatic heart disease Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000021139 traditional diet Nutrition 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a functional tea for preventing and improving cardiovascular and cerebrovascular diseases and a preparation method thereof, wherein the dry raw materials of the functional tea comprise: 20-30 parts of kudzuvine root, 10-20 parts of cyclocarya paliurus, 10-20 parts of thorn tea, 5-10 parts of mulberry leaf, 5-10 parts of grape seed, 5-10 parts of hovenia dulcis thumb, 5-10 parts of sea buckthorn fruit and 5-10 parts of golden camellia; the preparation method comprises the following steps: (1) weighing each dry raw material according to the formula; (2) crushing the dried raw materials and then sterilizing; and (3) adding water, boiling, filtering and cooling to obtain the beverage. The invention aims to provide functional tea for preventing and improving cardiovascular and cerebrovascular diseases through metabolic regulation and a preparation method thereof.
Description
Technical Field
The invention relates to the field of functional foods, in particular to functional tea for preventing and improving cardiovascular and cerebrovascular diseases and a preparation method thereof.
Background
In 2019, cardiovascular and cerebrovascular diseases, mainly coronary artery diseases (atherosclerosis affects the arteries supplying blood to the heart) and stroke (atherosclerosis affects the arteries supplying blood to the brain), cause nearly 1800 million deaths worldwide, and make atherosclerosis become the main lethal cause globally.
Atherosclerosis is the most common disease in cardiovascular and cerebrovascular diseases, is caused by the combined action of multiple factors, has a complex pathogenesis, and is not completely clarified at present. The main risk factors are hypertension, hyperlipidemia and massive smoking, and diabetes, obesity, genetic factors and the like, so the lipid-lowering and anti-inflammatory treatment is particularly important for resisting atherosclerosis. The targeted anti-inflammatory, blood pressure reducing, blood fat reducing and blood sugar reducing treatment can effectively prevent and improve the occurrence and development of the pathological changes. At present, the main drugs for clinically treating inflammation comprise steroidal anti-inflammatory drugs and non-steroidal anti-inflammatory drugs, and the clinical application of the drugs is limited due to multiple adverse reactions and single target point of the drugs.
The plant source natural product is an important source of the anti-inflammatory drug, and has the characteristics of various structures and activities, wide action targets, small toxic and side effects and the like. The structure types of the plant-derived anti-inflammatory natural products which are found at present mainly comprise terpenes, flavonoids, alkaloids, polysaccharides and the like, such as ginkgolide B, ursolic acid, glycyrrhizic acid, chalcone, quercetin, baicalin, berberine and the like.
There is a large body of evidence that caloric restriction, exercise, hormones, and many natural products used in traditional herbal medicine can activate AMP-activated protein kinase (AMPK), such as betaine, berberine, quercetin, polyphenol resveratrol. Among them, resveratrol is most widely studied, and it activates AMPK and SIRT1 through various mechanisms; AMPK can activate stem cells and promote the directional differentiation of the stem cells so as to repair damaged tissues, and can activate autophagy to remove damaged mitochondria and other metabolic impurities in the cells, so that the cell state can be improved, and the cell activity can be improved. The hypothesis that activation of AMPK is beneficial for the prevention and treatment of a variety of chronic diseases is supported by a large body of evidence, and some AMPK agonists have also entered the clinical development stage.
Cardiovascular and cerebrovascular diseases are diseases which can be prevented, and the occurrence of cardiovascular diseases can be greatly reduced by scientific diet and regular life. But at present, the fast pace of life and the huge working pressure make it difficult for people to do scientific diet and regular work and rest, and factors such as chronic injury and aging of the body and the like cause a great part of the problems of heart and cerebral vessels with different degrees in the middle-aged and the elderly and even in young people. At present, western medicines are mainly used for treating the diseases, such as statins for treating atherosclerosis, blood fat regulating medicines, clopidogrel for resisting blood platelets and the like, and medicines for treating hypertension, such as the flat medicines and the sartan medicines, and the single-molecule compound medicines are used for treating symptoms but not root causes, can only relieve symptoms to a certain extent but not treat the diseases fundamentally, have obvious side effects, and are easy to generate drug resistance after long-term use. The effect of the related traditional Chinese medicine products is not obvious enough, and the related traditional Chinese medicine products only can play a role in relieving symptoms. Because the traditional Chinese medicine is a medicinal product, the traditional Chinese medicine has a plurality of limitations in use, and can be used only after the onset symptoms are obvious, so that the best opportunity for prevention and treatment is greatly missed.
Chinese people have a traditional health preservation for thousands of years, and like prevention and treatment of diseases by a food therapy method, wherein tea drinking is the most popular and convenient way. The traditional Chinese medicines are in the shape of tens of thousands of Chinese herbal medicines, most of which are plant medicines, and some of the Chinese herbal medicines have the effect of treating diseases and can be used as food, so that the Chinese herbal medicines are called as homology of medicine and food. Chinese landmass has a lot of unique food resources, and although the landmass is not determined to be used as a medicine, the healthcare function of the landmass is clear and is widely accepted by people. Therefore, the food-grade tea recipe with special functions is developed by adopting food resources and raw materials with homology of medicine and food, is the development trend of current health-preserving products, and has great potential and good prospect.
At present, a variety of health-care functional tea products exist in the market, but the real health-care effect is good, and few functional tea products are popular with people, and the main technical reasons are that the theoretical basis is lacked, the mechanism is not clear, the formula is not scientific, and the health-care function is single and weak. The pursuit of good health and long life is a dream of human beings, and the research of functional tea which is suitable for long-term drinking and can prevent and improve cardiovascular and cerebrovascular diseases is an urgent need of modern people for pursuing health.
Disclosure of Invention
Based on the problems, the invention aims to provide functional tea for preventing and improving cardiovascular and cerebrovascular diseases through metabolic regulation and a preparation method thereof.
Aiming at the problems, the following technical scheme is provided: a functional tea for preventing and improving cardiovascular and cerebrovascular diseases is characterized by being prepared from the following dry raw materials in parts by weight: 20-30 parts of kudzuvine root, 10-20 parts of cyclocarya paliurus, 10-20 parts of thorn tea, 5-10 parts of mulberry leaf, 5-10 parts of grape seed, 5-10 parts of hovenia dulcis thunb, 5-10 parts of sea buckthorn fruit and 5-10 parts of golden camellia.
A preparation method of functional tea for preventing and improving cardiovascular and cerebrovascular diseases is characterized by comprising the following steps:
(1) Weighing the raw materials of the dry product according to the formula;
(2) Crushing the dried raw materials and then sterilizing;
(3) Boiling in water, filtering, and cooling.
The invention is further configured that the step (2) is specifically as follows: feeding the dried raw materials into a pulverizer, pulverizing into 20-60 meshes, sterilizing and packaging.
The invention is further configured that the step (2) is specifically as follows: the dry raw materials are sent into a pulverizer to be pulverized into superfine powder of 800-1000 meshes, and then sterilized and subpackaged.
The invention is further configured that the step (2) is specifically as follows: feeding the dried raw materials into a pulverizer, pulverizing into 800-1000 meshes, sterilizing, and tabletting.
The invention is further configured that the step (3) is specifically as follows: adding 800-1000 parts of water into the crushed raw materials, boiling for 30-60 minutes, decocting with medium fire for 60-120 minutes, filtering, sterilizing, distilling and concentrating to obtain a concentrated solution, drying by a spray drying method to prepare instant granules, and subpackaging, wherein each part is prepared by hot water for drinking.
The invention is further configured that the step (3) is specifically as follows: adding 1500-2500 parts of water into the crushed raw materials, boiling for 30-60 minutes, then decocting for 60-120 minutes with medium fire, then filtering, sterilizing, cooling and directly drinking or filling into bottles to prepare bottled tea for drinking.
The pharmacological effects of the formula raw materials of the functional tea are as follows:
1, kudzu root: is one of 86 medicinal and edible plants published in 2012. Modern researches find that the kudzuvine root contains various compounds such as flavonoid, triterpenes, coumarin and the like, wherein puerarin is the main active ingredient of the kudzuvine root. Puerarin is a flavonoid compound, and has various pharmacological effects of enhancing immunity, enhancing myocardial contraction force, protecting myocardial cells, lowering blood pressure, resisting platelet aggregation, etc. The puerarin preparation is clinically used for treating coronary heart disease, angina, diabetic complications, chronic pharyngitis, eye diseases, cerebral infarction, parkinson's syndrome, sudden deafness and other diseases, and achieves certain curative effect.
2, cyclocarya paliurus: the cyclocarya paliurus is a new resource food approved in Wei Jiwei 2013 originally, and is a deciduous tree of cyclocarya of Juglandaceae. The cyclocarya paliurus leaves mainly contain chemical components such as polysaccharide, flavone and triterpenes, and pharmacological activity researches show that the water extract can promote islet cell proliferation, protect islet tissues, reduce blood sugar and regulate fat metabolism, prevent diabetes and complications thereof by inhibiting inflammation, and the cyclocarya paliurus leaves also have pharmacological activities of reducing blood fat, resisting lipid peroxidation and the like.
3, thorn tea: also known as "thorn tea", it is a rare plant of Rosaceae growing in Shunhuang mountain, yongzhou, hunan province, and can be added into tea for use as a medicine, the leaves grow seven branches, and the tea plant has thorns. Acacia catechu is a pure natural green tea, and sweet taste is the biggest characteristic of the Acacia catechu. The Roxburgh anomala tea is rich in tea polysaccharide, and has the effects of protecting islet cells, improving the oxidation resistance of an organism and removing free radicals on islet tissues. Promote the repair and regeneration of islet beta cells, increase insulin secretion and stabilize blood sugar. Modern medical research shows that the tea polysaccharide has the effects of reducing blood sugar, reducing blood fat, enhancing immunity, reducing blood pressure, slowing down heart rate, increasing coronary flow, resisting blood coagulation, thrombus and oxygen deficiency, promoting mononuclear macrophagy function, enhancing collective self-protection, resisting radiation and the like. The invention uses the Acacia catechu, not only utilizes the pharmacological function of the Acacia catechu, but also utilizes the characteristic that the natural polysaccharide is sweet in taste, greatly improves the taste of the product of the invention, and is more easily accepted by people.
4, mulberry leaf: is one of 86 medicinal and edible plants published in 2012. The mulberry leaves are rich in various amino acids, including 8 amino acids, mineral substances and vitamins which are necessary for human bodies, and also contain a large amount of flavonoids, wherein each kilogram of the mulberry leaves contains 17200 mg of calcium, 9875 mg of potassium, 306 mg of iron, 270 mg of manganese, 66 mg of zinc, 10mg of copper and 202 mg of magnesium, and the mulberry leaves are the first choice plants for beauty and health care. Researches show that the mulberry leaves mainly contain chemical components such as flavonoids, alkaloids, phenylpropanoids, volatile oil, steroids, organic acids and the like. The flavonoid component is one of the main active ingredients of the mulberry leaves, and the content of the flavonoid is about 1 to 3 percent of the dry weight of the mulberry leaves. Wherein flavonol and flavonol glycosides with quercetin and kaempferol as aglycons are the main flavonoids in folium Mori. Modern medical research shows that the active ingredients of the mulberry leaves have good hypoglycemic effect, and simultaneously have antioxidant activity, anti-tumor activity, blood fat reducing activity, anti-atherosclerosis activity and anti-inflammatory activity.
5, grape seeds: is the product obtained by sun-drying grape seeds and separating grape skin and grape stalks. The grape seed contains polyphenols, mainly catechin and proanthocyanidin. Catechin compounds including catechin, epicatechin and gallate thereof are main monomers in grape seeds, and are also constituent units of oligomeric and polymeric procyanidins. Grape seeds contain abundant oil accounting for 12-15 wt%, and the oil contains a large amount of unsaturated fatty acids, wherein the content of linoleic acid is 58-78%. The grape seed contains crude protein, amino acids, vitamins A, E, D, K, P, and trace elements such as calcium, zinc, iron, magnesium, copper, potassium, sodium, manganese, and cobalt. The grape seeds can resist oxidation and remove free radicals, and prevent the free radicals from damaging human cells. In vivo and in vitro experiments show that the antioxidant effect of the grape seed extract is 30-50 times of that of vitamin C and vitamin E. The super-strong antioxidant efficiency has the functions of removing free radicals, protecting organs and tissues of a human body, and preventing and treating more than 100 diseases caused by the free radicals, such as heart disease, cancer, premature senility, diabetes, arteriosclerosis and the like. The rich linoleic acid of the grape seeds can effectively reduce blood fat and protect blood vessel health.
6, hovenia dulcis thunb: is one of 86 medicinal and edible plants published in 2012. Researches show that the hovenia dulcis thunb contains the tricuspid, the beta-carboline, the hovenia dulcis thunb glycoside, the rhamnosine and the like, and has the effects of resisting lipid peroxidation, reducing blood pressure and the like. The raisin tree seed is natural selenium-rich fruit, can regulate and improve the immunity of human body, maintain the normal structure and function of cardiovascular system and has good effect of prolonging life. Meanwhile, the hovenia dulcis thunb can relieve alcoholism, enhance the activities of key enzymes of hepatic ethanol metabolism and antioxidase, accelerate the metabolism of ethanol in vivo, reduce the generation of free radicals and lipid peroxides and protect the integrity of hepatic cell membranes. Considering the wine culture in the traditional diet culture and the problems of three highs and fatty liver, the invention adds the hovenia dulcis thunb, which can not only relieve alcoholism and protect liver, but also reduce fat and blood pressure and protect the cardiovascular and cerebrovascular systems.
7, sea-buckthorn: is one of 86 medicinal and edible plants published in 2012. The seabuckthorn fruit is listed as a health care product in palace in the Yuanji Dynasty, the medical health care function of seabuckthorn is also recorded in pharmacopoeia of Jingzhu materia Medica in Qing dynasty, and seabuckthorn is formally listed in Chinese pharmacopoeia in 1977. The unsaturated fatty acid rich in fructus Hippophae oil can dissolve lipid on vascular wall and vascular wall deposit, reduce blood lipid, and soften blood vessel. The total flavonoids of seabuckthorn fruit oil can remove active oxygen free radicals, and has excellent prevention and treatment effects on ischemic cardiovascular diseases including coronary heart disease, angina pectoris, myocardial infarction, arrhythmia, myocardial ischemia and anoxia, heart failure and the like. It also has good therapeutic effect on myocarditis, rheumatic heart disease, and chronic cardiac insufficiency, and also has good effects in improving cardiac function, and relieving symptoms such as chest distress, palpitation, and short breath. The medical clinical application shows that the total flavonoids of seabuckthorn can reduce the hyperlipemia, reduce the blood viscosity, inhibit the platelet aggregation and improve the blood circulation. Reducing cholesterol and triglyceride in blood, reducing low density protein, increasing high density lipoprotein, restoring blood vessel elasticity, increasing coronary blood flow, reducing oxygen consumption of myocardium, and increasing cardiac function, and has the effects of resisting arrhythmia and myocardial ischemia, reducing myocardial infarction area, relieving angina pectoris, and improving cardiac function.
8, golden camellia: the new resource food approved by the original Ministry of health in 2010 is called tea family queen and has the reputation of pandas in the plant world. The golden camellia contains more than 400 nutrient substances beneficial to human health, and is one of plants with the most abundant nutritional and medicinal values in nature. Is rich in various natural nutrients such as tea polysaccharide, tea polyphenol, total saponin, total flavone, tea pigment, caffeine, protein, vitamin B1, vitamin B2, vitamin C, vitamin E, folic acid, fatty acid, beta-carotene and the like; the golden camellia contains dozens of amino acids such as theanine and threonine, and is rich in various natural organic trace elements such as germanium, selenium, molybdenum, zinc and vanadium which have important health care effects on human bodies, and macroelements such as potassium, calcium and magnesium. Modern medical research shows that the golden camellia can effectively reduce blood fat, improve various maladaptive symptoms caused by hypertension, reduce cholesterol and low-density lipoprotein in serum, promote insulin secretion, enhance immunity, regulate blood flow, prevent atherosclerosis, resist bacteria, diminish inflammation, clear away heat and toxic materials, relieve constipation, promote urination, remove dampness, promote liver metabolism, prevent cancer, inhibit tumor growth and the like while effectively reducing blood sugar and blood pressure.
The invention has the beneficial effects that:
the functional tea scientifically combines multiple food-grade and medicine-food homologous plants with definite effects obtained based on high-throughput screening, regulates human metabolism from different angles and improves physical functions; the raw materials of the medicine have synergistic effect, so that the effects of clearing organism inflammation, improving organism glycolipid acid metabolism, activating cell autophagy to clear metabolic waste, recovering cell activity, delaying organ senescence, activating stem cells to repair damaged endothelial tissues, supplementing special trace elements to strengthen cell functions and the like are achieved.
2, the functional tea can effectively repair the problems of the cardiovascular and cerebrovascular systems after being drunk frequently, particularly improve and eliminate atherosclerotic plaques, reduce hypertension, maintain the normal blood pressure, improve symptoms such as angina, chest distress and the like caused by the problem of blood supply of the heart, and can effectively prevent serious lethal causes such as coronary heart disease, heart failure, stroke, cerebral apoplexy and the like; it also has good therapeutic effect on diabetes, hyperlipidemia, hyperuricemia and insomnia.
3, in the formula of the functional tea, various components are rich in resveratrol, the functional tea is a natural antioxidant with strong effects, and has the effects of scavenging free radicals, resisting inflammation, activating metabolism, reducing blood sugar and blood fat, improving immunity, resisting aging and the like, and the various components are matched with each other, so that the half-life period is increased from 3 hours to nearly 24 hours, the effects are greatly ensured, and the problems that the half-life period of the conventional functional tea is short and the effects are difficult to last are solved.
4, in the formula of the functional tea, various plants have anti-inflammatory effect, and the effect is better after the functional tea is compounded. Most of natural plants are indirect activators, the effect is not obvious enough, the activation effect is ensured by the synergistic effect of combining a plurality of natural plant activators, and the effect is better than that of micromolecular AMPK activators in western medicines.
5, the functional tea can enhance the body function and the resistance when being used as a tea beverage, has an anti-aging function, is a very suitable health beverage for sub-health people and vast middle-aged and old people, has fragrant taste and fresh and moist mouthfeel after being matched with each component, greatly improves the salty and sour taste of common traditional Chinese medicine health tea, and is more easily accepted by people; meanwhile, the preparation method of the functional tea is simple, the operation is easy to carry out, the repeatability is good, and the efficacy of the functional tea is very stable.
Drawings
FIG. 1 is a graph showing the results of in vitro cell experiments in which the aqueous extract of the present invention reduced proinflammatory factors in test example 1 of the present invention;
FIG. 2 is a graph showing the results of an in vivo animal experiment in which the aqueous extract of the present invention reduced proinflammatory factors in test example 2 of the present invention;
FIG. 3 is a graph showing the results of a cell experiment in which the aqueous extract of the present invention activates AMPK enzyme in test example 3 of the present invention.
Detailed Description
The following detailed description of embodiments of the present invention is provided in connection with the accompanying drawings and examples. The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
Example 1
The dried product preparation raw materials of the functional tea in the embodiment are as follows: 20g of kudzuvine root, 20g of cyclocarya paliurus, 15g of thorn tea, 10g of mulberry leaf, 10g of grape seed, 5g of hovenia dulcis thunb, 10g of sea buckthorn fruit and 10g of golden camellia;
the preparation method of the functional tea comprises the following steps:
(1) Weighing the raw materials of the dry products according to the formula;
(2) Feeding the dry raw materials into a pulverizer, pulverizing to 50 meshes, sterilizing and packaging;
(3) Adding 1500g of water, boiling for 40 minutes, decocting with medium fire for 70 minutes, filtering, and cooling to obtain the final product.
Example 2
The dried product preparation raw materials of the functional tea in the embodiment are as follows: 25g of kudzuvine root, 15g of cyclocarya paliurus, 20g of thorn tea, 10g of mulberry leaf, 5g of grape seed, 10g of hovenia dulcis thunb, 5g of sea buckthorn fruit and 10g of golden camellia;
the preparation method of the functional tea comprises the following steps:
(1) Weighing the raw materials of the dry product according to the formula;
(2) Feeding the dry raw materials into a grinder, grinding the dry raw materials into superfine powder of 900 meshes, sterilizing and subpackaging;
(3) Adding 1000g of water into the crushed raw materials, boiling for 50 minutes, decocting for 90 minutes by using medium fire, filtering, sterilizing, distilling and concentrating to obtain a concentrated solution, drying by adopting a spray drying method to prepare instant granules, subpackaging, and preparing each part by using hot water for drinking.
Example 3
The dried functional tea prepared by the embodiment comprises the following raw materials: 30g of kudzuvine root, 10g of cyclocarya paliurus, 20g of thorn tea, 5g of mulberry leaf, 10g of grape seed, 10g of hovenia dulcis thunb, 10g of sea buckthorn fruit and 5g of golden camellia;
the preparation method of the functional tea comprises the following steps:
(1) Weighing the raw materials of the dry product according to the formula;
(2) Feeding the dried raw materials into a pulverizer, pulverizing into 1000 meshes, sterilizing, and tabletting with a tabletting machine;
(3) Adding 2000g of water into the crushed raw materials, boiling for 40 minutes, then decocting for 100 minutes by using medium fire, then filtering, sterilizing, cooling and directly drinking or filling to prepare bottled tea for drinking.
In order to prove that the functional tea provided by the invention can obviously reduce proinflammatory factors such as tumor necrosis factor-alpha (TNFa), interleukins (IL-1 beta, IL-6) and the like, the experimental data of the embodiment 1 are adopted to carry out in vitro cell experiments and in vivo animal experiments;
preparing the functional tea by adopting the experimental data of the example 1, then centrifugally filtering to remove solid matters, drying the filtered solution in a sterile fume hood to obtain dry powder, namely preparing the water extract of the functional tea for experiment;
test example 1: in vitro cell experiments
The specific implementation method comprises the following steps: dividing the cultured human primary brain capillary endothelial cells into an aqueous extract group, a control group and an LPS group, and respectively treating the three groups of cells; water extract group: pre-acting with 1mg/mL water extract for 1 hr, adding 10 μ g/mL Lipopolysaccharide (LPS) for 12 hr; control group: no treatment is carried out; LPS group: adding Lipopolysaccharide (LPS) only 10 μ g/mL for 12 hr; then detecting the contents of tumor necrosis factor-alpha, interleukin IL-1 beta and IL-6 in the supernatants of the three groups of cells by adopting an enzyme-linked immunosorbent assay (ELISA);
the experimental results are as follows: as shown in fig. 1, the in vitro cell experiment results show that the aqueous extract of the present invention can significantly reduce pro-inflammatory factors.
Test example 2: in vivo animal experiments
The specific implementation method comprises the following steps: randomly dividing 15 adult male mice into a control group, an LPS group and an aqueous extract group, wherein each group comprises 5 mice, and respectively treating the three groups of mice; control group: injecting 10mg/kg of dimethyl sulfoxide (DMSO) into the abdominal cavity of each mouse; LPS group: each mouse is injected with Lipopolysaccharide (LPS) 10mg/kg in the abdominal cavity to generate acute inflammatory reaction; water extract group: each mouse was injected intraperitoneally with 10mg/kg of Lipopolysaccharide (LPS) and 100mg/kg of an aqueous extract previously dissolved in dimethyl sulfoxide (DMSO); after the administration for 12 hours respectively, detecting the contents of TNF-alpha, IL-1 beta and IL-6 in the serum of the three groups of mice by enzyme-linked immunosorbent assay (ELISA);
the experimental results are as follows: as shown in fig. 2, the in vivo animal experiment results show that the aqueous extract of the present invention can significantly reduce pro-inflammatory factors.
In order to prove that the functional tea provided by the invention can more efficiently activate AMPK enzyme, the water extract prepared by the experimental data of the embodiment 1 is adopted to treat primary brain capillary endothelial cells, and the preparation method of the water extract is the same as the above.
Test example 3:
the specific implementation method comprises the following steps: dividing the cultured human primary brain capillary endothelial cells into a blank control group, an aqueous extract group and a positive control group, and respectively treating the three groups of cells; blank control group: acting with 1mg/ml dimethyl sulfoxide (DMSO) for 6 hours; water extract group: acting with 1mg/ml aqueous extract dissolved in dimethyl sulfoxide (DMSO) as organic solvent for 6 hr; positive control group: acting with 1 mu mol/ml small molecule AMPK activator for 6 hours; then, three groups of cells are collected for carrying out an immunoblotting experiment, and changes of mTOR kinase threonine 2441 site phosphorylation, AMPK threonine 172 site phosphorylation, mitogen-activated protein kinase ERK1/2 phosphorylation, ribosomal protein S6 phosphorylation and autophagy marker LC3A/B are detected, and housekeeping protein ACTIN is used as a reference for protein loading.
The experimental results are as follows: as shown in FIG. 3, the experimental results show that the aqueous extract of the present invention can activate AMPK enzyme more efficiently, about 3-5 times stronger than the positive control group; meanwhile, phosphorylation of the mTOR enzyme and ribosomal protein S6 downstream of the signaling pathway of the mTOR enzyme is better inhibited, which is a key regulatory mechanism for aging resistance, and autophagy is activated. In addition, phosphorylation of the mitogen-activated protein kinase ERK1/2 is also inhibited, which may promote better glucose metabolism in some insulin resistant cells.
The following specific clinical examples prove the remarkable effect of the functional tea of the invention on the prevention and improvement of cardiovascular and cerebrovascular diseases, and the following experimental cases respectively drink the functional tea with the volume of 1 liter for a plurality of times every day.
Clinical example 1
Somebody of week, male, age 55, before drinking: color ultrasound examination of the carotid artery revealed a plaque-like mid-echo in the right carotid artery, with a size of about 0.55cm by 0.18cm; after drinking the functional tea of the invention for 3 months: color ultrasonic examination of the carotid artery shows that no obvious abnormal plaque echo, no obvious stenosis and smooth blood flow.
Clinical example 2
Some young, male, 66 years old, before drinking: carotid color ultrasound examination showed bilateral multi-spot plaque echoes with 0.44cm x 0.18cm for left maximum plaque and 0.50cm x 0.44cm for right maximum plaque; after drinking the functional tea of the invention for 2 months: color ultrasound examination of the carotid artery revealed a left maximum plaque of 0.35cm x 0.3cm and a right maximum plaque of 0.42cm x 0.24cm, which was 55% smaller than before drinking.
Clinical example 3
King a certain, woman, 51 years old, before drinking: color ultrasonic examination of carotid artery shows that plaque-like medium echo with size of about 0.86cm x 0.28cm can be seen in left carotid artery; after drinking the functional tea of the invention for 1 month: color ultrasound examination of the carotid artery revealed a left plaque size of about 0.7cm x 0.2cm, which was 42% smaller than before drinking.
Clinical example 4
When a certain plum is aged 49 years old, the symptoms of the coronary heart disease, hypertension, fatty liver and other diseases of the original angina pectoris type are obviously improved after drinking the functional tea of the invention for 3 months.
Clinical example 5
A certain Liu, female, age 70, before drinking: carotid color ultrasound examination showed that plaque size in the right carotid was about 1.49cm by 0.23cm; after drinking the functional tea of the invention for 4 months: the plaque size of right carotid artery was about 1.17cm x 0.21cm, the plaque was significantly reduced, and the total hepatic sterol content was reduced from 5.48mmol/L to 4.71mmol/L.
Clinical example 6
Somebody hair, male, age 45, before drinking: carotid color ultrasound examination showed that right carotid plaque size was about 0.49cm x 0.15cm; after drinking the functional tea of the invention for 4 months: the plaque size of the right carotid artery was about 0.34cm x 0.15cm, the plaque was significantly reduced, and the total hepatic sterol content was reduced from 6.88mmol/L to 5.56mmol/L.
The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and variations can be made without departing from the technical principle of the present invention, and those modifications and variations assumed in the above are also considered to be within the protective scope of the present invention.
Claims (7)
1. A functional tea for preventing and improving cardiovascular and cerebrovascular diseases is characterized by being prepared from the following dry raw materials in parts by weight: 20-30 parts of kudzuvine root, 10-20 parts of cyclocarya paliurus, 10-20 parts of thorn tea, 5-10 parts of mulberry leaf, 5-10 parts of grape seed, 5-10 parts of hovenia dulcis thunb, 5-10 parts of sea buckthorn fruit and 5-10 parts of golden camellia.
2. The method for preparing the functional tea for preventing and improving cardiovascular and cerebrovascular diseases according to claim 1, comprising the steps of:
(1) Weighing the raw materials of the dry product according to the formula;
(2) Crushing the dried raw materials and then sterilizing;
(3) Boiling in water, filtering, and cooling.
3. The method for preparing functional tea for preventing and improving cardiovascular and cerebrovascular diseases according to claim 2, wherein the step (2) is specifically: the dry raw materials are sent into a pulverizer to be pulverized into 20-60 meshes, and then are sterilized and packaged.
4. The method for preparing functional tea for preventing and improving cardiovascular and cerebrovascular diseases according to claim 2, wherein the step (2) is specifically: the dry raw materials are sent into a pulverizer to be pulverized into superfine powder of 800-1000 meshes, and then sterilized and packaged.
5. The method for preparing functional tea for preventing and improving cardiovascular and cerebrovascular diseases according to claim 2, wherein the step (2) is specifically: the dry raw materials are sent into a pulverizer to be pulverized into 800-1000 meshes, sterilized and prepared into tablets by a tablet press.
6. The method for preparing functional tea for preventing and improving cardiovascular and cerebrovascular diseases according to claim 2, wherein the step (3) is specifically: adding 800-1000 parts of water into the crushed raw materials, boiling for 30-60 minutes, then decocting for 60-120 minutes with medium fire, then filtering, sterilizing, distilling and concentrating to obtain concentrated solution, finally drying by adopting a spray drying method to prepare instant granules, and subpackaging, wherein each part is prepared by using hot water for drinking.
7. The method for preparing functional tea for preventing and improving cardiovascular and cerebrovascular diseases according to claim 2, wherein the step (3) is specifically: adding 1500-2500 parts of water into the crushed raw materials, boiling for 30-60 minutes, then decocting for 60-120 minutes by using medium fire, then filtering, sterilizing, cooling and directly drinking or filling to prepare bottled tea for drinking.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211280653.0A CN115708533A (en) | 2022-10-19 | 2022-10-19 | Functional tea for preventing and improving cardiovascular and cerebrovascular diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211280653.0A CN115708533A (en) | 2022-10-19 | 2022-10-19 | Functional tea for preventing and improving cardiovascular and cerebrovascular diseases and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115708533A true CN115708533A (en) | 2023-02-24 |
Family
ID=85231195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211280653.0A Pending CN115708533A (en) | 2022-10-19 | 2022-10-19 | Functional tea for preventing and improving cardiovascular and cerebrovascular diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115708533A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111110792A (en) * | 2020-01-17 | 2020-05-08 | 杨波 | Rhizoma polygonati and ginseng tea for controlling sugar, regulating lipid, reducing viscosity, preventing and treating diabetes and complications thereof |
| CN111134259A (en) * | 2020-02-18 | 2020-05-12 | 聂旭清 | Beverage composition and preparation method thereof |
| CN111227067A (en) * | 2019-12-23 | 2020-06-05 | 上海赋康健康管理有限公司 | Non-drug intervention dietary food for promoting disease rehabilitation |
| CN112843172A (en) * | 2021-03-06 | 2021-05-28 | 郭宝叶 | Chinese and western medicinal composition for improving human body function and discharging harmful toxin, and its preparation method |
-
2022
- 2022-10-19 CN CN202211280653.0A patent/CN115708533A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111227067A (en) * | 2019-12-23 | 2020-06-05 | 上海赋康健康管理有限公司 | Non-drug intervention dietary food for promoting disease rehabilitation |
| CN111110792A (en) * | 2020-01-17 | 2020-05-08 | 杨波 | Rhizoma polygonati and ginseng tea for controlling sugar, regulating lipid, reducing viscosity, preventing and treating diabetes and complications thereof |
| CN111134259A (en) * | 2020-02-18 | 2020-05-12 | 聂旭清 | Beverage composition and preparation method thereof |
| CN112843172A (en) * | 2021-03-06 | 2021-05-28 | 郭宝叶 | Chinese and western medicinal composition for improving human body function and discharging harmful toxin, and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101776071B1 (en) | Composition containing red sword bean extract for anti-aging and whitening | |
| US20010006983A1 (en) | Multicomponent biological vehicle | |
| KR101613693B1 (en) | Composition for Prevention or Treatment of Skin Disease Comprising an Extract of Sargassum Horneri and Method of Preparing The Same | |
| KR20110048236A (en) | Compositions for prevention and improvement of cancer containing the extracts of native plants as an active ingredient | |
| KR20100127420A (en) | Composition for improving bioavailability of saponin | |
| KR20120003693A (en) | Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and l-carnitine | |
| CN101766274B (en) | Antioxidant functional food composition containing bamboo-leaves flavones | |
| KR102218823B1 (en) | Composition for anti-allergy comprising extract of lithospermum erythrorhizon | |
| KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
| KR100679853B1 (en) | Composition comprising the extract of Ailanthus altissima for the prevention or treatment of asthma and allergic disease | |
| KR20170082249A (en) | A composition for improving, preventing and treating digestion dysfunction, leukocyte reduce, bone marrow suppression by side effects after anti-cancer therapy comprising Rhus verniciflua stoke extract | |
| KR20140028293A (en) | A pharmaceutical composition comprising the combined extract of crataegi fructus and citri pericarpium for treating or preventing obesity or lipid-related metabolic disorder | |
| KR20190065084A (en) | pharmaceutical composition for antioxidant or antiinflammatory comprising extract of Lonicera caerulea L. var. edulis fruits | |
| KR101988102B1 (en) | Composition for anti-oxidation containing the complex extracts of white ginseng, Agrimonia pilosa, Salvia miltiorrhiza and Solidago virgaurea | |
| WO2008069604A1 (en) | Composition comprising the mixed herbal extract of aralia cordata thunb. and cimicifuga heracleifolia kom. for preventing and treating inflammatory disease and pain disease | |
| CN115708533A (en) | Functional tea for preventing and improving cardiovascular and cerebrovascular diseases and preparation method thereof | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| KR102282839B1 (en) | Composition for relieving or improving hangover | |
| KR101636608B1 (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
| KR20180086935A (en) | A composition for improving, preventing and treating arthritis comprising Stewartia koreana extract and Rhus verniciflua stokes extract | |
| KR102408908B1 (en) | A health functional food comprising composite material extract for preventing or treating obesity | |
| KR20150113434A (en) | A composition comprising the extract of ginseng seed for protecting brain cells and preventing, improving and treating depression | |
| KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
| KR20150039342A (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
| JP2014043432A (en) | Method of manufacturing granules or tablets formed after pelletizing mulberry twigs, mulberry leaves and red-sepaled evening primrose by ionized dextrin, and bioactivity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |